Meyer Handelman Co. Purchases 188 Shares of AbbVie Inc. (NYSE:ABBV)
Meyer Handelman Co. Purchases 188 Shares of AbbVie Inc. (NYSE:ABBV)
Meyer Handelman Co. increased its stake in AbbVie Inc. (NYSE:ABBV – Get Rating) by 0.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 130,455 shares of the company's stock after buying an additional 188 shares during the period. Meyer Handelman Co.'s holdings in AbbVie were worth $19,981,000 as of its most recent SEC filing.
据艾伯维公司最近提交给美国证券交易委员会(Securities and Exchange Commission，简称：美国证券交易委员会)的文件显示，该公司在第二季度增持了0.1%的美团股份。该公司持有130,455股该公司股票，在此期间又购买了188股。截至最近提交给美国证券交易委员会的文件，Meyer Handelman Co.持有的艾伯维股份价值19,981,000美元。
Several other institutional investors also recently added to or reduced their stakes in ABBV. Alliancebernstein L.P. increased its stake in AbbVie by 9.7% in the 4th quarter. Alliancebernstein L.P. now owns 3,120,561 shares of the company's stock worth $422,524,000 after buying an additional 275,034 shares during the period. Red Door Wealth Management LLC increased its stake in AbbVie by 3.8% in the 4th quarter. Red Door Wealth Management LLC now owns 4,068 shares of the company's stock worth $550,000 after buying an additional 148 shares during the period. Stonebridge Capital Advisors LLC increased its position in AbbVie by 3.8% during the 4th quarter. Stonebridge Capital Advisors LLC now owns 111,690 shares of the company's stock valued at $15,123,000 after purchasing an additional 4,047 shares during the period. CSS LLC IL increased its position in AbbVie by 6.4% during the 4th quarter. CSS LLC IL now owns 8,328 shares of the company's stock valued at $1,127,000 after purchasing an additional 500 shares during the period. Finally, Columbia Asset Management increased its position in AbbVie by 0.8% during the 4th quarter. Columbia Asset Management now owns 55,613 shares of the company's stock valued at $7,530,000 after purchasing an additional 445 shares during the period. Hedge funds and other institutional investors own 68.25% of the company's stock.
其他几家机构投资者最近也增持或减持了ABBV的股份。联合伯恩斯坦公司在第四季度增持了9.7%的艾伯维股份。在此期间，联合伯恩斯坦公司又购买了275,034股股票，现在持有3,120,561股该公司股票，价值422,524,000美元。红门财富管理有限责任公司在第四季度增持了3.8%的艾伯维股份。红门财富管理有限责任公司现在拥有该公司4,068股股票，价值55万美元，在此期间又购买了148股。Stonebridge Capital Advisors LLC在第四季度将其在AbbVie的头寸增加了3.8%。Stonebridge Capital Advisors LLC现在拥有111,690股该公司的股票，价值15,123,000美元，在此期间又购买了4,047股。CSS LLC IL在第四季度将其在AbbVie的头寸增加了6.4%。在此期间购买了另外500股后，CSS LLC IL现在拥有该公司8,328股股票，价值1,127,000美元。最后，哥伦比亚资产管理公司在第四季度将其在AbbVie的头寸增加了0.8%。哥伦比亚资产管理公司现在拥有55,613股该公司的股票，价值7，53万美元，在此期间又购买了445股。对冲基金和其他机构投资者持有该公司68.25%的股票。
AbbVie Stock Up 0.0 %
AbbVie股价上涨0.0%
ABBV stock opened at $143.06 on Friday. The firm has a 50 day moving average of $141.77 and a 200 day moving average of $149.53. The stock has a market capitalization of $252.94 billion, a PE ratio of 20.26, a price-to-earnings-growth ratio of 4.02 and a beta of 0.72. The company has a quick ratio of 0.75, a current ratio of 0.84 and a debt-to-equity ratio of 4.15. AbbVie Inc. has a 52 week low of $106.44 and a 52 week high of $175.91.
上周五，ABBV股价开盘报143.06美元。该公司的50日移动均线切入位在141.77美元，200日移动均线切入位在149.53美元。该股市值2,529.4亿美元，市盈率20.26倍，市盈率4.02倍，贝塔系数0.72。该公司的速动比率为0.75，流动比率为0.84，债务权益比为4.15。AbbVie Inc.的52周低点为106.44美元，52周高点为175.91美元。
AbbVie Announces Dividend
AbbVie宣布分红
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 15th. Shareholders of record on Friday, October 14th will be paid a dividend of $1.41 per share. This represents a $5.64 annualized dividend and a yield of 3.94%. The ex-dividend date of this dividend is Thursday, October 13th. AbbVie's payout ratio is 79.89%.
该公司最近还披露了季度股息，将于11月15日(星期二)支付。10月14日(星期五)登记在册的股东将获得每股1.41美元的股息。这意味着5.64美元的年化股息和3.94%的收益率。本次股息除息日期为10月13日星期四。艾伯维的派息率为79.89%。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
ABBV has been the topic of a number of research reports. Morgan Stanley cut their target price on shares of AbbVie from $191.00 to $188.00 and set an "overweight" rating on the stock in a research report on Monday, August 1st. Atlantic Securities cut their target price on shares of AbbVie from $178.00 to $162.00 and set a "neutral" rating on the stock in a research report on Monday, August 1st. Piper Sandler cut their target price on shares of AbbVie from $160.00 to $155.00 in a research report on Friday, July 29th. Argus cut their target price on shares of AbbVie from $165.00 to $155.00 and set a "buy" rating on the stock in a research report on Wednesday, August 24th. Finally, Barclays cut their target price on shares of AbbVie to $160.00 in a research report on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $159.35.
ABBV已经成为许多研究报告的主题。8月1日，摩根士丹利在一份研究报告中将艾伯维股票的目标价从191.00美元下调至188.00美元，并对该股设定了“增持”评级。大西洋证券在8月1日周一的一份研究报告中将AbbVie的股票目标价从178.00美元下调至162.00美元，并将该股的评级定为“中性”。派珀·桑德勒在7月29日星期五的一份研究报告中将艾伯维股票的目标价从160.00美元下调至155.00美元。8月24日周三，阿格斯在一份研究报告中将艾伯维股票的目标价从165.00美元下调至155.00美元，并对该股设定了“买入”评级。最后，巴克莱在8月9日周二的一份研究报告中将艾伯维股票的目标价下调至160.00美元。一名股票研究分析师将该股评级为卖出，6名分析师给予持有评级，9名分析师给予买入评级，一名分析师给予该股强烈买入评级。根据MarketBeat的数据，该股目前的共识评级为“适度买入”，共识目标价为159.35美元。
AbbVie Profile
AbbVie个人资料
(Get Rating)
(获取评级)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
艾伯维公司在世界各地发现、开发、制造和销售药品。该公司提供HUMIRA，用于注射治疗自身免疫和肠道Behçet‘s疾病；SKYRIZI用于治疗成人中到重度斑块型牛皮癣；RINVOQ，用于治疗成人患者的中到重度活动性类风湿性关节炎；IMBRUVICA，用于治疗成人慢性淋巴细胞白血病和小淋巴细胞淋巴瘤；以及VENCLEXTA，用于治疗成人慢性丙型肝炎病毒基因1-6感染。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on AbbVie (ABBV)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- 免费获取StockNews.com关于AbbVie的研究报告(ABBV)
- 华尔街对Datadog的热情会带来巨大的收益吗？
- MarketBeat：回顾一周9/19-9/23
- 为什么特斯拉的股票保持弹性？
- 小盘股的裁员是楼市的晴雨表吗？
- CrowdStrike是否会从增加每股收益指引中获得提振？
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Get Rating).
想看看其他对冲基金持有ABBV吗？访问HoldingsChannel.com获取艾伯维公司的最新13F文件和内幕交易。
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
接收AbbVie Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对AbbVie和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。